Grem J L, Cheson B D, King S A, Leyland-Jones B, Suffness M
Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20892.
J Natl Cancer Inst. 1988 Sep 21;80(14):1095-103. doi: 10.1093/jnci/80.14.1095.
Clinical trials conducted in the People's Republic of China and the United States of the antileukemic efficacy of the cephalotaxine esters are reviewed. Harrington has been incorporated into combination regimens for the treatment of newly diagnosed acute nonlymphocytic leukemia (ANLL) in China, and activity with cephalotaxine esters has also been noted in chronic myelogenous leukemia. While the investigational agent homoharringtonine has shown some activity in the United States in ANLL, investigator interest in the United States has waned because of toxicity and inconvenient schedules. The Chinese trials have used different schedules than have U.S. studies and have been associated with less toxicity. These trials provide new information that may lead to further investigations of the cephalotaxine esters in the United States.
对在中国和美国进行的关于头霉素酯抗白血病疗效的临床试验进行了综述。在中国，三尖杉酯碱已被纳入联合方案用于治疗新诊断的急性非淋巴细胞白血病（ANLL），并且在慢性粒细胞白血病中也观察到头霉素酯的活性。虽然研究药物高三尖杉酯碱在美国的ANLL中显示出一定活性，但由于毒性和给药方案不便，美国研究者的兴趣已减弱。中国的试验采用了与美国研究不同的给药方案，且毒性较小。这些试验提供了新的信息，可能会促使美国对头霉素酯进行进一步研究。
